Background
==========

Discontinuing potentially inappropriate medications is a foundational element of the broader de-adoption movement, which aims to use evidence-based health policy as one of several strategies to promote safe and appropriate prescribing ([@R2]; [@R49]). National health and professional organizations have drawn attention to the overuse of antibiotics ([@R15]), opioids ([@R3]; [@R9]), antipsychotics ([@R12]; [@R17]), sedative-hypnotics ([@R1]; [@R8]; [@R13]; [@R26]; [@R33]) and polypharmacy ([@R35]; [@R44]; Scottish Government 2018). Policies have been put in place to reduce the overuse of medications but have produced mixed outcomes. Careful assessment of the policy mechanisms that have failed is needed to avoid future implementation of pharmaceutical policies that may be ineffective or counterproductive, burdening health providers, consuming taxpayer resources and inconveniencing patients ([@R32]).

Sedative-hypnotic drugs, especially benzodiazepine receptor agonists such as alprazolam, diazepam, lorazepam, zolpidem and zopicolone, have been identified as a priority area for deprescribing among older adults ([@R49]). Benzodiazepines and Z-drugs are among the most frequently prescribed potentially inappropriate medications, especially for older women ([@R1]; [@R6]; [@R49]). The harms associated with their short- and long-term use are well documented ([@R25]) and include falls and fractures ([@R19]; [@R54]), cognitive impairment ([@R5]; [@R51]), automobile accidents ([@R27]) and higher mortality alone and in combination with opioids ([@R31]; [@R33]; [@R47]). There is a substantive body of clinical research assessing interventions to reduce benzodiazepine and Z-drug use that are amenable to implementation ([@R36]; [@R41]; [@R45]; [@R50]). Policy initiatives in support of clinical interventions should be informed by previous assessment of effectiveness and unintended harm ([@R30]; [@R40]). Here we examine and compare the outcomes of different jurisdictional-wide policies on the reduction of benzodiazepine and Z-drug use among community-dwelling adults.

Study Data and Methods
======================

Search strategy
---------------

A search was conducted for published articles evaluating the impact of regional or regulatory jurisdiction-wide policies aimed at limiting sedative-hypnotic use among community-dwelling older adults using Medline, Embase and PsychINFO from inception to January 2017, with search terms related to drug class policy and age and restricted to the English language. For drug class, we limited the MeSH terms and keywords specific to benzodiazepines and specific Z-drugs (eszopiclone, zopiclone, zaleplon and zolpidem). The policy concept was split into two related and required component terms. First, we included terms concerning "legislation," "policy," "public policy," "health policy," "program(s)," "patient education," "campaign(s)" and "practice guidelines" to broadly identify studies of policies. Second, we included terms suggestive of an intended outcome related to discontinuation or deprescribing of inappropriate or unnecessary medications: "deprescriptions," "inappropriate prescribing," "drug utilization," "drug prescriptions," "withdraw\*," "discontinu\*," "appropriate\*," "optim\*" and "prescri\*." To ensure that the policy targeted individuals aged 65 years and older, we included the search terms "aged" and "over 65." Through hand-searching of references, we identified additional papers and grey literature sources. We limited our results to studies published in English. Figure [1](#FG1){ref-type="fig"} details the results of the search and the subsequent screening process.
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Article screening and selection
-------------------------------

Article titles and abstracts were each screened independently by two reviewers for policies or programs that targeted a reduction in benzodiazepine and Z-drug use among older adults. Article selection criteria included applicability of a jurisdictional-level policy to reduce the use of benzodiazepines and Z-drugs, clear documentation of pre- and post-policy population rates of sedative-hypnotic use to evaluate the policy\'s effectiveness and inclusion of community-dwelling individuals over the age of 65. Exclusion criteria included long-term care settings, programs that were rolled out in clinical settings, individuals solely under the age of 65 and baseline and follow-up data not available in the publication or via follow-up with the author directly. Article selection was completed by one investigator and reviewed by a second investigator. Disagreements were addressed through dialogue until agreement was reached among the authors.

Data extraction
---------------

Data were extracted from full-text articles by two members of the investigator team using a data extraction form, which included fields for the nature of the policy intervention, the relevant contexts, the time frame and the baseline and follow-up change metrics in drug use.

Outcomes
--------

The primary outcome was the comparative effectiveness of each policy on reductions in population-based rates of benzodiazepine and Z-drug prescriptions. Absolute prescription change was calculated by comparing rates of sedative-hypnotic use pre- and post-policy implementation. The relative effectiveness of each policy was recorded as the relative change in prescription rates (absolute difference in post- vs. pre-policy rate/pre-policy rate). Although the unintended consequences of each policy were of interest, unintended outcomes were not always documented in the article or related articles and therefore were considered as a secondary outcome. We hand-searched the literature for each policy that was identified to ensure that, where possible, we captured the published unintended outcomes.

Study Results
=============

The search returned 1,083 titles and abstracts. We excluded 74 duplicates and retained 148 full articles for review. One article was added from an external source. Of these, nine independent studies evaluating seven different policies for reducing the use of benzodiazepine and Z-drug medications in community-dwelling adults were included in the final analysis.

Comparative effectiveness
-------------------------

The comparative effectiveness of each policy on a change in sedative-hypnotic drug use is shown in Table 1 (available at [www.longwoods.com/content/25857](https://www.longwoods.com/articles/images/04-Shaw-HPL-14-4-Table-1.pdf)). Prescriber monitoring was most effective during a two-year follow-up of New York State\'s benzodiazepine triplicate prescribing policy for seniors ([@R37]; [@R52]). The policy required physicians to obtain, pay for and transmit one of three copies of a serialized prescription form to state health authorities for surveillance for any senior receiving a benzodiazepine prescription. A 35% reduction in the number of seniors receiving monthly benzodiazepine prescriptions was reported after the first year post-policy, and a cumulative 53%--58% decrease was recorded over two years ([@R37]; [@R52]). Following a successful state-wide intervention involving prescriber monitoring and education in 2007, in 2014, Australia made a national regulatory change that involved the rescheduling of alprazolam from a "schedule 4" designation, like other benzodiazepines, to a "schedule 8" controlled substance designation, which led to its inclusion as a monitored drug ([@R43]). As with the New York triplicate prescription policy, this regulatory change introduced surveillance by state and territory health authorities for any patient prescribed alprazolam. In New South Wales, a 28% reduction in alprazolam use was achieved among 65--79-year-olds one year post-policy implementation and 39% for those 80 years and older.

Denmark implemented a number of public awareness campaigns designed to reduce the use of sedative-hypnotics beginning in 2003, and in 2008, the Danish National Board of Health introduced a driver\'s license restriction policy for seniors. The driving license policy diminished the use of long-acting and short-acting benzodiazepines and Z-drugs by 54% and 35%, respectively, over five years ([@R20]). Physicians were required to report patients taking a benzodiazepine or Z-drug based on duration of use and drug half-life guidelines. Driving safety regulations included that all long-acting benzodiazepine users have their driver\'s license revoked, short-acting benzodiazepine users have a one-year limited renewal imposed with mandatory cognitive testing, new users refrain from driving for four weeks and episodic users not drive the morning after ingestion.

An Australian regional awareness campaign aimed to promote non-pharmacological therapy for insomnia. The multifaceted campaign included healthcare provider engagement and education, public education and the development and distribution of patient education materials relating to non-drug alternatives for the treatment of insomnia. A 19% reduction in benzodiazepine use was observed and sustained over a two-year period ([@R18]).

The effect of delisting benzodiazepines from public insurance programs varied by country and by specific policy. The Netherlands experienced an 11%--14% reduction over a two-year period ([@R28]; [@R30]) and a one-year 5% reduction was observed in the US ([@R10]). France\'s financial incentive program for physicians was the least effective, with a 1.4% increase in the number of patients initiating benzodiazepines over the course of one year ([@R40]).

Unintended consequences
-----------------------

Two follow-up studies examined the consequences of the national rescheduling of alprazolam in Australia ([@R16]; [@R34]). The first reported an overall reduction in alprazolam and total benzodiazepine use among a small sample of patients enrolled in an opioid substitution program ([@R16]). The street drug price of alprazolam doubled from \$5 to \$10 per two-milligram tablet over the 12-month period. The second report examined coroner records to assess a change in overdose due to alprazolam and other benzodiazepines ([@R34]). Although overdose deaths involving alprazolam declined, there was a steady increase in any overdose death where a benzodiazepine contributed, suggesting that limiting access to individual benzodiazepines might not impact on overall benzodiazepine-related mortality. Similarly, the US Medicare Part D restriction of reimbursement policy for benzodiazepines in the US led to high rates of substitution with zolpidem, which was still covered under the policy program, and a significant increase in out-of-pocket spending for benzodiazepines ([@R10]; [@R11]). A parallel rise occurred in prescriptions for other classes of sedative-hypnotics such as antipsychotics ([@R7]). There was an increase in fracture rates observed among patients admitted to nursing homes, presumably because of substitutions with these other sedatives ([@R7]).

The New York State triplicate prescribing policy also had unintended outcomes ([@R22]). Within one year of the policy, prescriptions for barbiturates, meprobamate and other medications climbed, in contrast to the rest of the US, where their use was trending downward ([@R53]). Greater reductions in sedative-hypnotics were observed among women and individuals who were black and living in urban or low-income areas ([@R22]). Data also suggest that the policy detrimentally affected some clinically vulnerable populations (e.g., persons with chronic psychiatric and neurological disorders) ([@R22]).

Patient perceptions and physician receptivity in response to the administrative burden associated with prescription monitoring and other policies programs were analyzed ([@R22]; [@R42]). A survey was conducted of 302 physicians and 103 patients from a Hispanic community in New York State two years after implementation of the benzodiazepine triplicate prescription policy ([@R42]). Forty-nine per cent of physicians reported that the policy affected their prescribing patterns, with 86% citing the increased administrative burden as the main reason for diminishing prescriptions, and 78% expressing opposition to prescription monitoring. Sixty-eight per cent of patients surveyed were dissatisfied with the triplicate prescription policy owing to the need for government documentation, breach of confidentiality and increased costs because of additional physician visits. In Denmark, sharing of information occurred between government departments during the driver\'s license restriction policy but was framed in the context of new public driving safety legislation implemented in 2007 that targeted prescribed medications together with illicit substances that can impair driving ([@R46]).

Limitations
===========

Many of the reports relating to policy interventions are observational and retrospective, and only a small number purposively assessed unintended outcomes. In some cases, publication of the primary outcome and unintended outcomes was completed separately. We hand searched the literature to ensure that, where possible, we could present the published unintended outcomes. Our search did not find any negative outcomes from the drivers\' license policy in Denmark nor the educational campaign in Australia; it is possible that negative consequences occurred but remain undocumented. Furthermore, unintended outcomes may have occurred at a clinical level and these would not have been captured. We limited our review to published peer-reviewed papers and did not scan government websites or the grey literature for other policies that were implemented. As policies do not have fixed evaluation periods and are situated within different contexts, it is difficult to compare the effectiveness of each policy, even with a generic calculation such as the relative reduction in use. We chose to study pharmaceutical policy for community-dwelling older adults. Policies that have been applied to reduce benzodiazepine use in acute or long-term care settings were not included, and the results of this analysis may not be generalizable to other contexts.

Other potentially effective solutions may exist that were not captured in this review. For instance, we did not find any jurisdictional-wide interventions that examined the effectiveness of policies to restrict pharmaceutical industry-based product promotion, for example via direct-to-consumer advertising ([@R4]). Policies that aim to reduce the promotion of prescription drugs to prescribers and directly to patients require further investigation ([@R23]; [@R24]). Nor did we find any assessments of jurisdiction-wide deprescribing initiatives that occurred at the patient level, rather than at the drug level. Medication reviews and deprescribing frameworks that address the patient\'s goals of care should be applied more broadly to patients with multimorbidity and polypharmacy in the clinical setting ([@R44]). Patient-specific interventions to deprescribe demonstrate a significant reduction in mortality ([@R39]).

Discussion
==========

The benefits of deprescribing policies may be diminished by a host of unanticipated consequences. Prescription monitoring policies such as the New York triplicate prescription policy led to the highest rates of discontinuation, but substitution with other inappropriate medication classes and the emergence of inequities undermined the intended effect. Financial deterrents through insurance scheme delistings were only minimally impactful and increased patient out-of-pocket spending. Financial incentivization in the form of a pay-for-performance supplement to prescribers was ineffective. Rescheduling alprazolam to a controlled substance that requires monitoring raised the street drug price of the drug and shifted use to other medications from the same class that caused similar rates of overdose deaths. Denmark\'s driver license policy and Australia\'s regional educational campaign on non-drug alternatives for treating insomnia were the only two policies that did not report unintended harms.

Extrapolation of the findings from policies targeting sedative-hypnotics to other drug classes such as opioids -- given the current opioid abuse epidemic -- would be useful, but is challenging to do. Prescription monitoring to reduce opioid prescribing has been shown to be modestly effective in some but not all jurisdictions in the US, particularly when it is part of a mandated program and covers the full range of prescription opioids ([@R3]). Similar to the Australian alprazolam policy, however, substitution with other medications from the same class and a rise in illicit access and street drug costs can occur when a single opioid drug is targeted for restriction ([@R32]). Intensive and inclusive educational awareness programs that target the public, patients and health professionals to encourage use of non-drug substitutes appear to be moderately effective, at least for reducing sedative-hypnotics in the short term. The long-term sustainability and unforeseen consequences of time-limited education and awareness campaigns targeting sedative-hypnotics, opioids or other medication classes have yet to be fully elucidated ([@R9]). Widespread availability of opioids, while emphasizing alternative approaches and tools for the treatment of chronic pain, emerges as a promising approach associated with a substantially lower population-wide usage of opioids in Japan ([@R21]).

Because opioids are implicated in three-quarters of benzodiazepine-related overdose deaths ([@R29]), parallel educational policies should be entertained and examined for sedatives and opioids. The EMPOWER study, that distributed direct-to-patient educational material on the harms of benzodiazepines, easy-to-follow tapering protocols and suggestions for non-drug alternates, yielded a 27% termination in chronic benzodiazepine use at the six-month follow-up versus 5% in the treatment as usual group ([@R50]). Additional benefit occurs with the combined use of patient education and pharmacist-initiated distribution of evidence-based pharmaceutical opinions to physicians to support patients to deprescribe and adopt non-drug therapies for symptom relief ([@R36]). Opportunities exist to encourage dialogue and legislation around drugs and driving safety when entertaining policies to reduce motor vehicle accidents. Patient-oriented policies have been proposed in the context of brain health and dementia strategies ([@R14]). The Canadian Deprescribing Network serves as a national hub in Canada for the promotion of evidence-informed initiatives and partnerships with policy makers, healthcare providers and the general public to reduce medication-related harm and improve access to non-drug therapies ([@R49]).

Challenges exist when comparing pharmaceutical policies to reduce medication overuse both within and across drug classes. To evaluate the magnitude of effect of each policy on medication reduction, methodological considerations include the use of different metrics and length of follow-up periods for each policy evaluation, the inability to evaluate policies that are not recorded in the medical literature, the lack of adequate explanation of contextual and cultural factors impacting the policy and widely different indications and determinants of use. Evidence-based policy also requires a hard look at downstream consequences, assessing trade-offs between specific goals ([@R2]). Although prescriptions plummeted with prescriber monitoring and medication rescheduling policies, substitutions with equally and more harmful medications increased and the demand for street drug availability rose, leading to higher rates of morbidity and mortality. Direct and indirect costs are rarely ascertained in the real-world setting, though economic simulations suggest that access to and coverage of non-drug therapies may prove cost-effective, particularly for older adults with insomnia ([@R38]; [@R48]).

The effort to generate policies that are effective at reducing the overuse of particular prescription drugs, that do not lead to pernicious consequences and that are acceptable to stakeholders requires close attention to political and health system contexts. Success will depend on the design, drug class, implementation details and the program particulars for each jurisdiction. Health promotion educational interventions that target specific patients may be the safest and most reasonable solution.
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